Cystic Fibrosis Drug a Game Changer?
Experimental Drug Ivacaftor May Extend Lives of Cystic Fibrosis Patients
Dramatic Improvement in Lung Function continued...
“When you consider that the typical cystic fibrosis patient loses about 2% of lung function a year, a 17% improvement in lung function is remarkable,” Beall says.
The ivacaftor-treated patients also saw dramatic reductions in their sweat’s chloride content -- an indication that the drug was working, as researchers had hoped, to modify the disease process by restoring the balance of salt and water within the body.
“When I first saw the results, I thought they couldn’t be real,” researcher Bonnie Ramsey, MD, of Seattle Children’s Hospital and the University of Washington School of Medicine tells WebMD. “You just don’t see changes like this.”
FDA Considering Ivacaftor Approval
Most patients in the study have remained on the drug, and researchers will present an additional 12 weeks of follow-up this week at the 25th Annual North American Cystic Fibrosis Conference in Anaheim, Calif., later this week.
They will also present data on children between the ages of 6 and 11 with the mutation who were treated with the experimental drug.
Cambridge, Mass.-based Vertex Pharmaceuticals, which is developing ivacaftor, is also developing a second experimental drug for use in patients with the most common cystic fibrosis gene mutation -- F508del.
About 90% of patients carry this mutation, and phase II trials are now under way to determine if the combination of the two experimental drugs can improve outcomes in these patients.
Vertex spokeswoman Dawn Kalmar says the FDA is reviewing the data on ivacaftor and the drug could be approved as early as the middle of next year.
Could Treating Babies Stop Disease?
Case Western University vice president for medical affairs Pamela B. Davis, MD, PhD, says there is real hope that the treatment approach will extend the lives of patients and improve quality of life for many years.
There is also the potential to stop the disease in its tracks if the drugs can be safely given to infants and very young children, she says.
Because early screening for cystic fibrosis is now the law in all 50 states, most cases of the disease are identified in newborns.
“We now have a chance to prevent lung damage from occurring if we can treat early enough,” she says. “That would be tremendously exciting.”
Human Genome Project, Gates Foundation Played Part
In an editorial published with the study, Davis writes that the experimental drugs are the result of more than two decades of intense private and publicly funded research, beginning with the discovery of the cystic fibrosis gene in 1989.
This included a $20 million grant to the Cystic Fibrosis Foundation from the Bill & Melinda Gates Foundation in 1999 to research new drugs -- the largest single grant ever given to the foundation.
Davis says the research shows that much of the promise of the Human Genome Project, which made the discovery of the cystic fibrosis gene possible, has yet to be fulfilled.
“It took us 22 years to get to this point with a whole lot of resources and collaboration to develop screening tests and drugs,” she tells WebMD. “I think one lesson here is stay tuned. We ain’t seen nothing yet from the Human Genome Project.”